OncoMatch/Clinical Trials/NCT06926075
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Is NCT06926075 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including A novel hGIIA-Vimentin Inhibitor and Dose expansion for prostate cancers.
Treatment: A novel hGIIA-Vimentin Inhibitor · Dose expansion — This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Ovarian Cancer
Glioblastoma
Pancreatic Cancer
Melanoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Platelet count > 100 x 10^9/L; Hb > 9.0 g/dL; ANC > 1.5 x 10^9/L
Kidney function
Creatinine < 1.5 x ULN
Liver function
AST and ALT < 3 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases; total bilirubin ≤ 1.5 x ULN; serum albumin ≥ 2.5 g/dL
Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below: Platelet count > 100 x 10^9/L; Hb > 9.0 g/dL; ANC > 1.5 x 10^9/L; Creatinine < 1.5 x ULN; AST and ALT < 3 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases; Total bilirubin ≤ 1.5 x ULN; Serum albumin ≥ 2.5 g/dL; INR/PT and APTT ≤ 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06926075 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages